|
End-of-day quote
Berne S.E.
28/08/2026
|
5-day change | 1st Jan Change | ||
| 132.24 CHF | +0.75% |
|
-0.17% | -8.71% |
| 06:53pm | IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy | MT |
| 03:39pm | Hutchmed Says Lung Cancer Therapy Improves Progression-Free Survival in China Phase 3 Trial | MT |
| Market Cap | 252B 217B 204B 186B 349B 23,952B 351B 2,412B 938B 12,146B 945B 925B 40,216B | P/E 2026 * |
20.9x | P/E 2027 * | 18.3x |
|---|---|---|---|---|---|
| Enterprise Value | 271B 233B 219B 200B 376B 25,791B 378B 2,597B 1,010B 13,078B 1,018B 996B 43,303B | EV / Sales 2026 * |
4.29x | EV / Sales 2027 * | 3.94x |
| Free-Float |
96.63% | Yield 2026 * |
2.06% | Yield 2027 * | 2.19% |
Last Transcript : AstraZeneca PLC
| 1 day | +0.75% | ||
| 1 week | -0.17% | ||
| Current month | -7.11% | ||
| 1 month | -7.11% | ||
| 3 months | -10.90% | ||
| 6 months | -13.16% | ||
| Current year | -8.71% |
| 1 week | 131.25 |  | 134.6 |
| 1 month | 124.91 | | 134.6 |
| Current year | 124.91 | | 163 |
| 1 year | 116.75 | | 163 |
| 3 years | 104.86 | | 163 |
| 5 years | 95 | | 163 |
| 10 years | 52.7 | | 163 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 66 | 01/10/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 01/08/2021 |
Jeffrey Pott
CMP | Compliance Officer | - | 01/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 06/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 66 | 01/10/2012 |
Philip Broadley
BRD | Director/Board Member | 65 | 27/04/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.75% | -0.17% | - | - | 252B | |
| -1.43% | -7.35% | +57.14% | +108.46% | 1,047B | |
| -0.81% | -2.57% | +49.39% | +64.53% | 646B | |
| +0.83% | -2.71% | +21.44% | +75.12% | 451B | |
| -1.64% | -4.75% | +35.59% | +35.54% | 355B | |
| -0.39% | -2.76% | +21.39% | +38.01% | 291B | |
| -1.19% | -2.21% | +1.53% | +11.51% | 252B | |
| -0.52% | -2.99% | +50.07% | +67.97% | 234B | |
| -1.05% | -2.29% | -19.91% | -54.10% | 203B | |
| +0.53% | -0.06% | +30.11% | +91.75% | 181B | |
| Average | -0.62% | -2.68% | +27.42% | +48.75% | 406.59B | |
| Weighted average by Cap. | -0.82% | -3.46% | +36.55% | +64.82% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 63.25B 54.46B 51.13B 46.68B 87.69B 6,018B 88.32B 606B 236B 3,052B 237B 232B 10,105B | 66.84B 57.55B 54.04B 49.33B 92.66B 6,360B 93.33B 640B 249B 3,225B 251B 246B 10,678B |
| Net income | 12.02B 10.35B 9.72B 8.87B 16.67B 1,144B 16.79B 115B 44.81B 580B 45.14B 44.16B 1,921B | 13.61B 11.72B 11B 10.04B 18.87B 1,295B 19B 130B 50.73B 657B 51.1B 49.99B 2,174B |
| Net Debt | 19.33B 16.64B 15.62B 14.26B 26.79B 1,839B 26.98B 185B 72.03B 932B 72.56B 70.99B 3,087B | 11.65B 10.03B 9.42B 8.6B 16.15B 1,109B 16.27B 112B 43.43B 562B 43.75B 42.8B 1,862B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/08/26 | CHF 132.24 | +0.75% | 1 |
| 27/08/26 | CHF 131.25 | -2.49% | 70 |
| 25/08/26 | CHF 134.60 | +0.22% | 175 |
| 24/08/26 | CHF 134.30 | +1.39% | 5 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AZN Stock
- 000982352 Stock
Select your edition
All financial news and data tailored to specific country editions
